Quantitative Proteomics-based Prostate Cancer Prediction Models for African American and Caucasian American Patients
EMSL Project ID
60597
Abstract
In this research project, the Pacific Northwest National Laboratory (PNNL) research team will support the project by conducting quantitative proteomics analysis using mass spectrometry to identify biomarkers of prostate cancer (PCa) aggressiveness in a racially diverse cohort of men. This proposal specifically addresses biological factors that may contribute to racial disparities in incidence and outcomes.The project defines its study population as male patients self-reporting as African American (AA) and Caucasian American (CA) who underwent one or more transrectal ultrasound (TRUS)-guided biopsies for suspicion of prostate cancer at University Hospital (UH) system or Cleveland Clinic Foundation (CCF) in Cleveland, OH. These hospitals treat a large number of prostate cancer patients annually; at UH, approximately 40% of newly diagnosed patients are AA.
The study aims of this collaborative project are as follows:
Aim 1: To conduct a global deep discovery analysis among African American and Caucasian patients to develop a model based on biopsy-tissue derived proteomic markers that can distinguish between three groups of men—20 patients in each group for a total of 60 subjects to be examined in Aim 1:
a. men under suspicion for prostate cancer but who have no evidence of disease based on 2 or more negative TRUS-guided biopsy procedures
b. men who are detected with metastatic (i.e., N+/M+) prostate cancer at initial diagnosis
c. men who are detected with indolent (cT1-2a, Gleason sum <6) prostate cancer at diagnosis
Aim 2: Quantitative proteomic biomarkers of prostate cancer development and aggressiveness from both our preliminary data that was based on RP as the tissue source and biomarkers from Aim 1 above, using earliest biopsy tissue available will be verified in an expanded retrospective cohort using sensitive, precise and multiplexed targeted proteomic assays, with an emphasis on examining the role of patient self-reported race/ethnicity, to help distinguish these 3 cohort subsets (a-c above). Novel markers discovered in Aim 1 will be of interest, as will the validation of markers already identified in the preliminary study conducted. A total of 250 subjects will be examined in Study Aim 2.
Project Details
Start Date
2022-09-27
End Date
N/A
Status
Active
Released Data Link
Team
Principal Investigator
Co-Investigator(s)
Team Members